137 research outputs found
Low power arcjet system spacecraft impacts
Application of electrothermal arcjets on communications satellites requires assessment of integration concerns identified by the user community. Perceived risks include plume contamination of spacecraft materials, induced arcing or electrostatic discharges between differentially charged spacecraft surfaces, and conducted and radiated electromagnetic interference (EMI) for both steady state and transient conditions. A Space Act agreement between Martin Marietta Astro Space, the Rocket Research Company, and NASA's Lewis Research Center was established to experimentally examine these issues. Spacecraft materials were exposed to an arcjet plume for 40 hours, representing 40 weeks of actual spacecraft life, and contamination was characterized by changes in surface properties. With the exception of the change in emittance of one sample, all measurable changes in surface properties resulted in acceptable end of life characteristics. Charged spacecraft samples were benignly and consistently reduced to ground potential during exposure to the powered arcjet plume, suggesting that the arcjet could act as a charge control device on spacecraft. Steady state EMI signatures obtained using two different power processing units were similar to emissions measured in a previous test. Emissions measured in UHF, S, C, Ku and Ka bands obtained a null result which verified previous work in the UHF, S, and C bands. Characteristics of conducted and radiated transient emissions appear within standard spacecraft susceptibility criteria
Ion-Energy Plume Diagnostics on the BHT-600 Hall Thruster Cluster
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/76547/1/AIAA-20514-735.pd
Recommended from our members
De novo SCN2A splice site mutation in a boy with autism spectrum disorder
BACKGROUND:
SCN2A is a gene that codes for the alpha subunit of voltage-gated, type II sodium channels, and is highly expressed in the brain. Sodium channel disruptions, such as mutations in SCN2A, may play an important role in psychiatric disorders. Recently, de novo SCN2A mutations in autism spectrum disorder (ASD) have been identified. The current study characterizes a de novo splice site mutation in SCN2A that alters mRNA and protein products.
CASE PRESENTATION:
We describe results from clinical and genetic characterizations of a seven-year-old boy with ASD. Psychiatric interview and gold standard autism diagnostic instruments (ADOS and ADI-R) were used to confirm ASD diagnosis, in addition to performing standardized cognitive and adaptive functioning assessments (Leiter-R and Vineland Adaptive Behavior Scale), and sensory reactivity assessments (Sensory Profile and Sensory Processing Scales). Genetic testing by whole exome sequencing revealed four de novo events, including a splice site mutation c.476 + 1G > A in SCN2A, a missense mutation (c.2263G > A) causing a p.V755I change in the TLE1 gene, and two synonymous mutations (c.2943A > G in the BUB1 gene, and c.1254 T > A in C10orf68 gene). The de novo SCN2A splice site mutation produced a stop codon 10 amino acids downstream, possibly resulting in a truncated protein and/or a nonsense-mediated mRNA decay. The participant met new DSM-5 criteria for ASD, presenting with social and communication impairment, repetitive behaviors, and sensory reactivity issues. The participant's adaptive and cognitive skills fell in the low range of functioning.
CONCLUSION:
This report indicates that a splice site mutation in SCN2A might be contributing to the risk of ASD. Describing the specific phenotype associated with SCN2A mutations might help to reduce heterogeneity seen in ASD
Timed sequential chemotherapy with concomitant Granulocyte Colony-Stimulating Factor for high-risk acute myelogenous leukemia: a single arm clinical trial
BACKGROUND: The timed-sequential chemotherapy regimen consisting of etoposide, mitoxantrone and cytarabine (EMA) is an effective therapy for relapsed or refractory acute myelogenous leukemia (AML). We postulated that granulocyte colony-stimulating factor (G-CSF) might enhance the cytotoxicity of EMA by increasing the proportion of leukemic blasts in S-phase. We added G-CSF to EMA (EMA-G) for therapy of advanced high-risk AML patients. METHODS: High-risk AML was defined as refractory, relapsed or secondary to either an antecedent hematologic disorder or exposure to cytotoxic agents. The patients were treated with one course of EMA-G consisting of mitoxantrone and cytarabine on days 1–3, and etoposide and cytarabine on days 8–10. G-CSF was started on day 4 and continued until absolute neutrophil count recovered. RESULTS: Thirty patients were enrolled. The median age was 51 years (range, 25–75). Seventeen (61%) patients had unfavorable cytogenetic karyotypes. Twenty (69%) patients had secondary AML. Ten (34%) had relapsed disease. Four (14%) had refractory AML. Three (10%) patients died from febrile neutropenia and sepsis. Major non-hematologic toxicity included hyperbilirubimenia, renal insufficiency, mucositis, diarrhea, nausea and vomiting, skin rash. A complete remission was achieved in 13 (46%) patients. Median overall survival was 9 months (range, 0.5–66). Median relapse-free survival (RFS) for those who had a CR was 3 months (range, 0.5–63) with RFS censored at the time of allogeneic bone marrow transplantation or peripheral stem cell transplantation for 6 of the patients. CONCLUSIONS: EMA-G is a safe and efficacious option for induction chemotherapy in advanced, high-risk AML patients. The activity of EMA may be increased if applied in patients with less advanced disease
A sensitive chemical procedure for monitoring the radiolytic oxidation of proteins at γ-ray dosages down to 1 Krad
- …